Home
Abbott Header Logo
Logo

Home > Offerings > All Products > Genetics & Genomics > AneuVysion Multicolor DNA Probe Kit

Aneuvysion® Multicolor Dna Probe Kit

ANEUVYSION background color
ANEUVYSION background color
ANEUVYSION background color

For In Vitro Diagnostic Use

The AneuVysion Multicolor DNA Probe Kit (Vysis CEP 18/X/Y - alpha satellite / LSI 13/21), which utilizes fluorescence in situ hybridization (FISH) technology applied to uncultured or cultured amniocytes, provides detection of trisomies 13, 18, and 21 (Down syndrome) and sex chromosome aneusomies in as little as 24 hours.

AneuVysion Multicolor DNA Probe Kit Package Insert (PDF - 851 KB)

For Information Only - Not a Controlled Copy

Together, trisomies 13, 18, and 21 (Down syndrome) and sex chromosome aneusomies account for nearly 57% of all abnormalities identified at the time of amniocentesis, and 85-90% of clinically significant chromosomal abnormalities detected in live-born infants. Review of AneuVysion testing of over 29,000 amniotic fluid samples has found that the test is 99.9% specific with 99.6% sensitivity for the detection of trisomies 13, 18, 21, and aneusomies of X and Y.
 

AneuVysion Kit Contents

Each AneuVysion kit includes:

  • CEP 18/X/Y and LSI 13/21 probes packaged in two probe mixtures 
  • Wash reagents NP-40 and 20X SSC
  • DAPI II counterstain
  • Package insert with instructions for use

CEP 18/X/Y and LSI 13/21 are pre-mixed with Blocking DNA and Hybridization Buffer.

Intended Use

For In Vitro Diagnostic Use

The AneuVysion (Vysis CEP 18, X, Y-alpha satellite, LSI 13 and 21) Multicolor Probe Panel is intended to use CEP 18/X/Y probe to detect alpha satellite sequences in the centromere regions of chromosomes 18, X, and Y, and LSI 13/21 probe to detect the 13q14 region and the 21q22.13 to 21q22.2 region. The AneuVysion kit is indicated for identifying and enumerating chromosomes 13, 18, 21, X, and Y via FISH in metaphase cells and interphase nuclei obtained from amniotic fluid in subjects with presumed high risk pregnancies. It is not intended to be used as a stand alone assay for making clinical decisions. FISH results are intended to be used as an aid in the diagnosis of numerical abnormalities of chromosomes 13, 18, 21, X and/or Y in conjunction with other information currently used in prenatal diagnosis, consistent with professional standards of practice.1 This device is intended for use only with amniocyte cells; it is not intended for and has not been validated for use with other test matrices. This FISH assay will not detect the presence of structural chromosome abnormalities that can also result in birth defects. This FISH assay will be performed in cytogenetics laboratories. 

Limitations

  1. The AneuVysion kit has been characterized only for identifying targeted regions of chromosomes X, Y, 18, 13, and 21 in interphase nuclei from uncultured and cultured amniocyte specimens.
  2. The clinical interpretation of any test result(s) should be made in conjunction with other diagnostic laboratory test results and should be evaluated within the context of the patient’s medical history and current risk factors. Clinical decision making should be based on information from FISH and at least 1 of the following results: confirmatory standard chromosome analysis or consistent clinical information, such as an abnormal ultrasound finding or a positive screening test result for Down syndrome or trisomy 18.1,2-4
  3. FISH assay results may not be informative if the specimen quality and/or specimen slide preparation is inadequate.
  4. This assay will not detect the presence of structural abnormalities frequently associated with birth defects. The frequency of these occurrences may be population and gestational age dependent.
  5. This assay should not be performed on amniocyte specimens with moderate to severe maternal cell contamination. FISH test results on amniocyte specimens with mild maternal cell contamination should be interpreted with caution.
  6. No irreversible therapeutic action should be initiated based on a positive FISH assay alone. Positive results should be further characterized using standard chromosome analysis to determine the mutational mechanism accounting for the abnormality detected by FISH. This information may aid in counseling for the risk that the detected abnormality may occur in future pregnancies.1-2
  7. Physicians, counselors, and other healthcare providers should understand the risk of abnormalities that the test is not designed to detect. The patient should be informed that there is still a very small risk of low level mosaicism, cryptic translocations, or other undetectable events that may not be demonstrated by FISH or standard cytogenetics. Additionally, there is a very small risk that some individuals carry a genetic polymorphism that may affect the intensity, presence or absence of the probe signal that may result in a missed diagnosis.5
  8. When the specimen volume is not sufficient to meet the minimum requirements for processing both FISH and standard cytogenetic procedures, the user must carefully weigh the risks and benefits of utilizing any material for FISH. Consultation between the laboratory geneticist and/or genetic counselor and the patient’s physician may aid in clarifying what information is desired, and which testing method should be used.1
  9. Technologists performing the FISH signal enumeration must be capable of visually distinguishing between the orange, green and aqua signals.
  10. Although the probe for enumerating chromosome 13 spans the Rb1 locus, this probe has not been validated for detecting mutations associated with retinoblastoma. In rare cases, the Rb1 locus may be deleted; this could complicate interpretation of FISH test results.

References

  1. American College of Medical Genetics. Technical and clinical assessment of fluorescence in situ hybridization: an ACMG/ASHG position statement. I. Technical considerations. Genet Med. 2000;2(6):356-361. 
  2. ACOG Practice Bulletin No. 88: Invasive Prenatal Testing for Aneuploidy. Obstet Gynecol. 2007;110(6):1459-67.
  3. Cunniff C, et al. Prenatal screening and diagnosis for pediatricians. Pediatrics. 2004;114(3):889-94.
  4. Hong Kong College of Obstetricians and Gynaecologists. Guidelines for genetic amniocentesis. HKCOG Guidelines [serial online]. July 2000;4:1-4. Available at:http://www.hkcog.org.hk/docs/guidelines/Genetic%20Amniocentesis_2000.pdf. Accessed April 19, 2010.
  5. Tepperberg J, Pettenati MJ, Rao PN, et al. Prenatal diagnosis using interphase fluorescence in situ hybridization (FISH): two-year multi-center retrospective study and review of the literature. Prenat Diagn. 2001;21(4):293-301.
Logo

© 2026 Abbott, Abbott Park, Illinois, U.S.A.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. Other trademarks are the property of their respective owners.

This Internet site that you have requested is intended for the residents of a particular country or countries and may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which this site is directed, contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

YOU ARE ABOUT TO EXIT THE ABBOTT FAMILY OF WEBSITES FOR A 3RD PARTY WEBSITE

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?